1.Laude A, Cackett PD, Vithana EN, Yeo IY, Wong D, Koh AH, Wong TY, Aung T: Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: same or different disease? Progress in retinal and eye research 2010, 29(1):19–29.
2.Imamura Y, Engelbert M, Iida T, Freund KB, Yannuzzi LA: Polypoidal choroidal vasculopathy: a review. Survey of ophthalmology 2010, 55(6):501–515.
3.Ma L, Brelen ME, Tsujikawa M, Chen H, Chu WK, Lai TY, Ng DS, Sayanagi K, Hara C, Hashida N et al: Identification of ANGPT2 as a New Gene for Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in the Chinese and Japanese Populations. Investigative ophthalmology & visual science 2017, 58(2):1076–1083.
4.De Salvo G, Vaz-Pereira S, Keane PA, Tufail A, Liew G: Sensitivity and specificity of spectral-domain optical coherence tomography in detecting idiopathic polypoidal choroidal vasculopathy. American journal of ophthalmology 2014, 158(6):1228–1238 e1221.
5.Moussa K, Bloomer MM, Schwartz DM, Pan CK, Toy BC, Crawford JB, Afshar AR: Polypoidal Choroidal Vasculopathy: A Clinicopathologic Study. Retinal cases & brief reports 2017, 11 Suppl 1:S128-S131.
6.Jin E, Bai Y, Huang L, Zhao M, Zhang C, Zhao M, Li X: Evidence of a novel gene HERPUD1 in polypoidal choroidal vasculopathy. International journal of clinical and experimental pathology 2015, 8(11):13928–13944.
7.Balaratnasingam C, Lee WK, Koizumi H, Dansingani K, Inoue M, Freund KB: Polypoidal Choroidal Vasculopathy: A Distinct Disease or Manifestation of Many? Retina 2016, 36(1):1–8.
8.Adamus G: Can innate and autoimmune reactivity forecast early and advance stages of age-related macular degeneration? Autoimmunity reviews 2017, 16(3):231–236.
9.Knickelbein JE, Chan CC, Sen HN, Ferris FL, Nussenblatt RB: Inflammatory Mechanisms of Age-related Macular Degeneration. International ophthalmology clinics 2015, 55(3):63–78.
10.Mimura T, Funatsu H, Noma H, Shimura M, Kamei Y, Yoshida M, Kondo A, Watanabe E, Mizota A: Aqueous Humor Levels of Cytokines in Patients with Age-Related Macular Degeneration. Ophthalmologica Journal international d’ophtalmologie International journal of ophthalmology Zeitschrift fur Augenheilkunde 2019, 241(2):81–89.
11.Hu J, Leng X, Hu Y, Atik A, Song X, Li Z, Liu Y, Lu L: The Features of Inflammation Factors Concentrations in Aqueous Humor of Polypoidal Choroidal Vasculopathy. PloS one 2016, 11(1):e0147346.
12.Fu B, Liu ZL, Zhang H, Gu F: Interleukin–13 and age-related macular degeneration. International journal of ophthalmology 2017, 10(4):535–540.
13.Sakurada Y, Nakamura Y, Yoneyama S, Mabuchi F, Gotoh T, Tateno Y, Sugiyama A, Kubota T, Iijima H: Aqueous humor cytokine levels in patients with polypoidal choroidal vasculopathy and neovascular age-related macular degeneration. Ophthalmic research 2015, 53(1):2–7.
14.Agrawal R, Balne PK, Wei X, Bijin VA, Lee B, Ghosh A, Narayanan R, Agrawal M, Connolly J: Cytokine Profiling in Patients With Exudative Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy. Investigative ophthalmology & visual science 2019, 60(1):376–382.
15.Balne PK, Agrawal R, Au VB, Lee B, Ghosh A, Sethu S, Agrawal M, Narayanan R, Connolly J: Dataset of plasma and aqueous humor cytokine profiles in patients with exudative age related macular degeneration and polypoidal choroidal vasculopathy. Data in brief 2018, 19:1570–1573.
16.Forooghian F, Kertes PJ, Eng KT, Albiani DA, Kirker AW, Merkur AB, Fallah N, Cao S, Cui J, Or C et al: Alterations in intraocular cytokine levels following intravitreal ranibizumab. Canadian journal of ophthalmology Journal canadien d’ophtalmologie 2016, 51(2):87–90.
17.Yan X, Dai X, He L, Ling X, Shao M, Zhang C, Wang Y, Xiao J, Cai L, Li X et al: A Novel CXCR4 antagonist enhances angiogenesis via modifying the ischaemic tissue environment. Journal of cellular and molecular medicine 2017, 21(10):2298–2307.
18.Laiva AL, Raftery RM, Keogh MB, O’Brien FJ: Pro-angiogenic impact of SDF–1alpha gene-activated collagen-based scaffolds in stem cell driven angiogenesis. International journal of pharmaceutics 2018, 544(2):372–379.
19.Davidi S, Fremder E, Kan T, Raviv Z, Timaner M, Karin N, Hershkovitz D, Arohneim A, Shaked Y: The antiangiogenic role of the pro-inflammatory cytokine interleukin–31. Oncotarget 2017, 8(10):16430–16444.
20.Yang XF, Huang YX, Lan M, Zhang TR, Zhou J: Protective Effects of Leukemia Inhibitory Factor on Retinal Vasculature and Cells in Streptozotocin-induced Diabetic Mice. Chinese medical journal 2018, 131(1):75–81.
21.Byrne AM, Roche SL, Ruiz-Lopez AM, Jackson AC, Cotter TG: The synthetic progestin norgestrel acts to increase LIF levels in the rd10 mouse model of retinitis pigmentosa. Molecular vision 2016, 22:264–274.
22.Hollborn M, Reichmuth K, Prager P, Wiedemann P, Bringmann A, Kohen L: Osmotic induction of placental growth factor in retinal pigment epithelial cells in vitro: contribution of NFAT5 activity. Molecular biology reports 2016, 43(8):803–814.
23.Hussain RM, Ciulla TA: Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration. Expert opinion on emerging drugs 2017, 22(3):235–246.
24.Agawa T, Usui Y, Wakabayashi Y, Okunuki Y, Juan M, Umazume K, Kezuka T, Takeuchi M, Yamauchi Y, Goto H: Profile of intraocular immune mediators in patients with age-related macular degeneration and the effect of intravitreal bevacizumab injection. Retina 2014, 34(9):1811–1818.
25.Jonas JB, Tao Y, Neumaier M, Findeisen P: Cytokine concentration in aqueous humour of eyes with exudative age-related macular degeneration. Acta ophthalmologica 2012, 90(5):e381–388.
26.Rezar-Dreindl S, Sacu S, Eibenberger K, Pollreisz A, Buhl W, Georgopoulos M, Krall C, Weigert G, Schmidt-Erfurth U: The Intraocular Cytokine Profile and Therapeutic Response in Persistent Neovascular Age-Related Macular Degeneration. Investigative ophthalmology & visual science 2016, 57(10):4144–4150.
27.Ten Berge JC, Fazil Z, van den Born I, Wolfs RCW, Schreurs MWJ, Dik WA, Rothova A: Intraocular cytokine profile and autoimmune reactions in retinitis pigmentosa, age-related macular degeneration, glaucoma and cataract. Acta ophthalmologica 2019, 97(2):185–192.
28.Kramer M, Hasanreisoglu M, Feldman A, Axer-Siegel R, Sonis P, Maharshak I, Monselise Y, Gurevich M, Weinberger D: Monocyte chemoattractant protein–1 in the aqueous humour of patients with age-related macular degeneration. Clinical & experimental ophthalmology 2012, 40(6):617–625.
29.Jonas JB, Tao Y, Neumaier M, Findeisen P: Monocyte chemoattractant protein 1, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1 in exudative age-related macular degeneration. Archives of ophthalmology 2010, 128(10):1281–1286.
30.Fauser S, Viebahn U, Muether PS: Intraocular and systemic inflammation-related cytokines during one year of ranibizumab treatment for neovascular age-related macular degeneration. Acta ophthalmologica 2015, 93(8):734–738.
31.Campochiaro PA, Hafiz G, Mir TA, Scott AW, Zimmer-Galler I, Shah SM, Wenick AS, Brady CJ, Han I, He L et al: Pro-permeability Factors in Diabetic Macular Edema; the Diabetic Macular Edema Treated With Ozurdex Trial. American journal of ophthalmology 2016, 168:13–23.
32.Mo FM, Proia AD, Johnson WH, Cyr D, Lashkari K: Interferon gamma-inducible protein–10 (IP–10) and eotaxin as biomarkers in age-related macular degeneration. Investigative ophthalmology & visual science 2010, 51(8):4226–4236.
33.Funk M, Karl D, Georgopoulos M, Benesch T, Sacu S, Polak K, Zlabinger GJ, Schmidt-Erfurth U: Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab. Ophthalmology 2009, 116(12):2393–2399.